U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a new federal initiative to build a comprehensive autism data platform using Medicare and Medicaid records. Designed to study the causes of autism spectrum disorder (ASD), the platform will integrate claims data, electronic health records, and data from wearable health devices, according to the Department of Health and Human Services (HHS).
The National Institutes of Health (NIH) and the Centers for Medicare and Medicaid Services (CMS) will collaborate on the effort, which is part of a broader $50 million research initiative to investigate potential environmental and medical causes of autism. Kennedy stated the project aims to provide "honest answers families have waited far too long to hear," despite his controversial history promoting a debunked link between vaccines and autism.
HHS said the platform will help researchers analyze autism diagnoses, treatment outcomes, healthcare access disparities, and the financial impact on families. However, experts like Dr. Helen Tager-Flusberg of Boston University argue the focus does not directly address autism’s root causes. She also noted that an existing NIH autism database recently went offline without explanation, raising concerns about transparency.
The project has sparked privacy questions, as HHS has not confirmed whether the database will be anonymous or voluntary. Autism researcher Eric Rubenstein noted that Medicaid and Medicare data offer insights into health disparities but lack environmental exposure data, which Kennedy claims he will explore.
Autism rates have surged in recent years, with the CDC reporting 1 in 31 U.S. 8-year-olds diagnosed in 2022. While Kennedy aims to identify autism’s causes by September, scientists emphasize that autism likely stems from a complex mix of genetic and environmental factors. Critics warn against oversimplifying this ongoing scientific challenge.


China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Trump Allows Commercial Fishing in Protected New England Waters
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Illinois Joins WHO Global Outbreak Network After U.S. Exit, Following California’s Lead
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 



